Core Viewpoint - HCM's stock price increased by 2.33% to $16.25 per share, with a total market capitalization of $2.834 billion as of August 21 [1] Financial Performance - As of June 30, 2025, HCM reported total revenue of $278 million, a year-on-year decrease of 9.16% [1] - The net profit attributable to the parent company reached $455 million, showing a significant year-on-year increase of 1663.32% [1] Company Overview - HCM is recognized as one of the first innovative pharmaceutical research and development companies in China focused on the global market [1] - Over the past 20 years, the company has established a comprehensive and integrated R&D innovation platform with world-class discovery and development capabilities [1] - HCM is dedicated to bringing self-discovered anti-tumor candidate drugs to global patients, with its first three drugs already launched in China and the first drug also available in the United States [1] - The company has built a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer healthcare products [1] - HCM is listed on the NASDAQ Global Select Market, the Hong Kong Stock Exchange, and the AIM market of the London Stock Exchange [1]
和黄医药(US ADR)上涨2.33%，报16.25美元/股，总市值28.34亿美元